Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Ding, Guanxiong ^a   Feng, Chenchen ^a   Jiang, Haowen ^a   Ding, Qiang ^a   Zhang, Limin ^a   Na, Rong ^a   Xu, Hua ^a   Liu, Jun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANDROGEN; ANDROGEN RECEPTOR; BIM PROTEIN; CASPASE 3; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; TANESPIMYCIN; TRANSCRIPTION FACTOR SLUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE; GENE EXPRESSION REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SLUG GENE; TOXICITY TESTING; TUMOR INVASION;

ANDROGENS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BENZOQUINONES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 84885398079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077400     Document Type: Article

References (28)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8-29. doi:10.3322/canjclin.54.1.8. PubMed: 14974761.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66. doi:10.3322/canjclin.57.1.43. PubMed: 17237035.
3. Chen Y, Clegg NJ, Scher HI, (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10: 981-991. doi:10.1016/S1470-2045(09)70229-3. PubMed: 19796750.
4. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, et al. (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227. doi:10.1016/S0002-9440(10)63112-4. PubMed: 14695335.
5. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, et al. (2003) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97: 739-747. doi:10.1002/cncr.11181. PubMed: 12548571.
6. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, et al. (2007) Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383. doi:10.1002/jcp.21223. PubMed: 17680632.
7. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, et al. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197-209. doi:10.1016/j.ccr.2005.07.009. PubMed: 16169465.
8. Liu J, Uygur B, Zhang Z, Shao L, Romero D, et al. (2010) Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression. Prostate 70: 1768-1777. PubMed: 20564361.
9. Nollet F, Berx G, van Roy F, (1999) The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 2: 77-85. doi:10.1006/mcbr.1999.0155. PubMed: 10542129.
10. Hajra KM, Fearon ER, (2002) Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34: 255-268. doi:10.1002/gcc.10083. PubMed: 12007186.
11. Peinado H, Portillo F, Cano A, (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48: 365-375. doi:10.1387/ijdb.041794hp. PubMed: 15349812.
12. Malumbres M, Pellicer A, (1998) RAS pathways to cell cycle control and cell transformation. Front Biosci 3: 887-912. PubMed: 9696882.
13. Nawshad A, Lagamba D, Polad A, Hay ED, (2005) Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179: 11-23. doi:10.1159/000084505. PubMed: 15942189.
14. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, et al. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84-89. doi:10.1038/35000034. PubMed: 10655587.
15. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83. doi:10.1038/35010506. PubMed: 10655586.
16. McCluggage WG, (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43: 420-432. doi:10.1097/PAT.0b013e328348a6e7. PubMed: 21716157.
17. Martin KA, Blenis J, (2002) Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 86: 1-39. doi:10.1016/S0065-230X(02)86001-8. PubMed: 12374276.
18. Ivanova L, Butt MJ, Matsell DG, (2008) Mesenchymal transition in kidney collecting duct epithelial cells. Am J Physiol Renal Physiol 294: F1238-F1248. doi:10.1152/ajprenal.00326.2007. PubMed: 18322023.
19. Saegusa M, Hashimura M, Kuwata T, Okayasu I, (2009) Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol 174: 2107-2115. doi:10.2353/ajpath.2009.081018. PubMed: 19389926.
20. Wu J, Ru NY, Zhang Y, Li Y, Wei D, et al. (2011) HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug. Oncogene 30: 4410-4427. doi:10.1038/onc.2011.149. PubMed: 21532623.
21. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, et al. (2008) Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68: 2479-2488. doi:10.1158/0008-5472.CAN-07-2559. PubMed: 18381457.
22. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183. doi:10.1210/er.22.2.153. PubMed: 11294822.
23. Kolch W, (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. J Biochem 351: 289-305. doi:10.1042/0264-6021:3510289. PubMed: 11023813.
24. Janknecht R, Ernst WH, Pingoud V, Nordheim A, (1993) Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J 12: 5097-5104. PubMed: 8262053.
25. Csermely P, Schnaider T, Soti C, Prohászka Z, Nardai G, (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79: 129-168. doi:10.1016/S0163-7258(98)00013-8. PubMed: 9749880.
26. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39. doi:10.1038/nm972. PubMed: 14702632.
27. Waltering KK, Urbanucci A, Visakorpi T, (2012) Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 360: 38-43. doi:10.1016/j.mce.2011.12.019. PubMed: 22245783.
28. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, et al. (2013) Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 42: 35-43. PubMed: 23152004.